Zuogui pills maintain the stemness of oogonial stem cells and alleviate cyclophosphamide-induced ovarian aging through Notch signaling pathway

Lihua Zeng; Jinfei Ye; Zhaoping Zhang; Yunyi Liang; Jing Li; Lei Zeng; Lei Cao; Ling Zhu; Songping Luo

doi:10.1016/j.phymed.2022.153975

Zuogui pills maintain the stemness of oogonial stem cells and alleviate cyclophosphamide-induced ovarian aging through Notch signaling pathway

Phytomedicine. 2022 May:99:153975. doi: 10.1016/j.phymed.2022.153975. Epub 2022 Feb 3.

Authors

Lihua Zeng¹, Jinfei Ye¹, Zhaoping Zhang¹, Yunyi Liang¹, Jing Li², Lei Zeng³, Lei Cao³, Ling Zhu⁴, Songping Luo²

Affiliations

¹ Guangzhou University of Chinese Medicine, Guangzhou 510006, China; Lingnan Medical Research Center of Guangzhou University of Chinese Medicine, Guangzhou 510006, China.
² Department of Gynecology, First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou 510006, China; Lingnan Medical Research Center of Guangzhou University of Chinese Medicine, Guangzhou 510006, China.
³ Department of Gynecology, First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou 510006, China.
⁴ Department of Gynecology, First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou 510006, China; Lingnan Medical Research Center of Guangzhou University of Chinese Medicine, Guangzhou 510006, China. Electronic address: zhulinggyn@hotmail.com.

PMID: 35217439
DOI: 10.1016/j.phymed.2022.153975

Abstract

Background: Zuogui pills (ZGP), a classical prescription of traditional Chinese medicine, have been widely used in the treatment of ovarian aging. Previous studies have demonstrated its efficacy on protecting ovarian aging, and the mechanisms were mostly relevant to inhibiting the apoptosis of follicles and activating the primordial follicles. However, whether ZGP could stimulate the oogonial stem cells (OSCs) to refresh the follicle pool remains poorly understood.

Purpose: To investigate the effects of ZGP on the stemness of OSCs in cyclophosphamide (Cy)-induced ovarian aging.

Study design and methods: Female Sprague-Dawley (SD) rats were randomly divided into 8 groups: control group, model group, ZGP groups (low / high dose groups), estradiol valerate (EV) groups (low / high dose groups), DAPT group and DAPT+ZGP-L group. After modeling with Cy, the ZGP groups and EV groups were treated with ZGP and EV for 8 weeks respectively. Meanwhile, the DAPT groups were treated with DAPT twice a week. Additionally, OSCs were also isolated after modeling, and then treated with drug serum containing ZGP or EV. Ovarian volume and the ratio of weight of total ovaries to the body weight were measured. The serum hormones were measured by ELISA. Quantities and location of OSCs in ovaries were detected by flow cytometry and immunofluorescence. Cell viability was measured by CCK8. And OSCs were identified by immunofluorescence. Biomarkers of germ cells, stem cells and associated to differentiation and meiosis were detected by qPCR and western blot. Proteins in Notch signaling pathway were detected by western blot and immunofluorescence.

Results: After treating with ZGP, ovarian volume and the ratio of weight of total ovaries to the body weight increased. ZGP could increase serum AMH and E₂ level and decrease serum FSH level. Quantities and cell viability of OSCs increased after ZGP treatment in vivo and in vitro. In addition, treatment with ZGP could increase not only the expression of MVH, Oct4 and DAZL, but also the expression of ZP1 and ZP2. Furthermore, ZGP could up-regulate the expression of Notch intracellular domain (NICD), HES1 and HES5. After blocking the Notch signaling pathway, ZGP could increase not only the expression of NICD, HES1 and HES5, but also the expression of MVH, Oct4, DAZL, ZP1 and ZP3.

Conclusion: In conclusion, the mechanism of ZGP on treating ovarian aging may be relevant to maintain the stemness of OSCs by up-regulating Notch signaling pathway, which added the mechanism of ZGP on the perspective of OSCs at first time.

Keywords: Notch signaling pathway; OSCs; Ovarian aging; Stemness; Zuogui pills.